- Novel class of highly lipophilic camptothecins, known as Karenitecins, demonstrates potent oral antitumor activity, acceptable safety and appear to be insensitive to common tumor-associated drug resistance mechanisms
- BioNumerik's novel chemoprotecting agent BNP7787 appears to completely protect against major toxicities associated with widely used platinum anticancer drugs such as cisplatinum
New Orleans, LA - March 30, 1998 -- BioNumerik Pharmaceuticals, Inc. this week presented new research results on two novel supercomputer-engineered small molecule agents designed to help address significant existing problems in current cancer therapy. These results continue to strengthen the correlation between actual experimental observations and the computational simulations provided by BioNumerik's innovative supercomputer simulations and mechanism based approach to new pharmaceutical discovery and development.
Regarding BioNumerik's BNP7787 and Karenitecins, Martin D. Abeloff, M.D., Director of the Johns Hopkins Oncology Center, stated, "These drugs have the potential to make a significant impact on current cancer therapy. The data reported by BioNumerik is particularly meaningful because the discovery and design of both of these agents was supported by BioNumerik's mechanism based computational studies and supercomputer simulations."
Frederick H. Hausheer, M.D., BioNumerik's Chairman and Chief Executive Officer, presented these findings at the 89th Annual Meeting of the American Association for Cancer Research held March 28 - April 1, 1998.
In a presentation titled "Karenitecins: A Novel Class of Orally Active Highly
Lipophilic Topoisomerase I Inhibitors", the results presented by BioNumerik of
studies conducted in BALB/c mice indicate that orally administered Karenitecin
had excellent antitumor activity against solid tumors (prostate, colon, breast,
lung) and had superior antitumor potency compared to existing camptothecin
Contact: Neil Cohen
212-696-4455 x. 205